BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Berna MJ, Seiz O, Nast JF, Benten D, Bläker M, Koch J, Lohse AW, Pace A. CCK1 and CCK2 receptors are expressed on pancreatic stellate cells and induce collagen production. J Biol Chem. 2010;285:38905-38914. [PMID: 20843811 DOI: 10.1074/jbc.m110.125534] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Benten D, Kluwe J, Wirth JW, Thiele ND, Follenzi A, Bhargava KK, Palestro CJ, Koepke M, Tjandra R, Volz T, Lutgehetmann M, Gupta S. A humanized mouse model of liver fibrosis following expansion of transplanted hepatic stellate cells. Lab Invest. 2018;98:525-536. [PMID: 29352225 DOI: 10.1038/s41374-017-0010-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
2 Osborne N, Sundseth R, Burks J, Cao H, Liu X, Kroemer AH, Sutton L, Cato A, Smith JP. Gastrin vaccine improves response to immune checkpoint antibody in murine pancreatic cancer by altering the tumor microenvironment. Cancer Immunol Immunother 2019;68:1635-48. [PMID: 31549214 DOI: 10.1007/s00262-019-02398-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
3 Smith JP, Cooper TK, McGovern CO, Gilius EL, Zhong Q, Liao J, Molinolo AA, Gutkind JS, Matters GL. Cholecystokinin receptor antagonist halts progression of pancreatic cancer precursor lesions and fibrosis in mice. Pancreas. 2014;43:1050-1059. [PMID: 25058882 DOI: 10.1097/MPA.0000000000000194] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
4 Wang HC, Hung WC, Chen LT, Pan MR. From Friend to Enemy: Dissecting the Functional Alteration of Immunoregulatory Components during Pancreatic Tumorigenesis. Int J Mol Sci 2018;19:E3584. [PMID: 30428588 DOI: 10.3390/ijms19113584] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
5 Birtolo C, Go VL, Ptasznik A, Eibl G, Pandol SJ. Phosphatidylinositol 3-Kinase: A Link Between Inflammation and Pancreatic Cancer. Pancreas 2016;45:21-31. [PMID: 26658038 DOI: 10.1097/MPA.0000000000000531] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
6 Radoslavova S, Folcher A, Lefebvre T, Kondratska K, Guénin S, Dhennin-Duthille I, Gautier M, Prevarskaya N, Ouadid-Ahidouch H. Orai1 Channel Regulates Human-Activated Pancreatic Stellate Cell Proliferation and TGFβ1 Secretion through the AKT Signaling Pathway. Cancers (Basel) 2021;13:2395. [PMID: 34063470 DOI: 10.3390/cancers13102395] [Reference Citation Analysis]
7 Nadella S, Ciofoaia V, Cao H, Kallakury B, Tucker RD, Smith JP. Cholecystokinin Receptor Antagonist Therapy Decreases Inflammation and Fibrosis in Chronic Pancreatitis. Dig Dis Sci 2020;65:1376-84. [PMID: 31598921 DOI: 10.1007/s10620-019-05863-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Smith JP, Fonkoua LK, Moody TW. The Role of Gastrin and CCK Receptors in Pancreatic Cancer and other Malignancies. Int J Biol Sci 2016;12:283-91. [PMID: 26929735 DOI: 10.7150/ijbs.14952] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 7.2] [Reference Citation Analysis]
9 Malchiodi ZX, Cao H, Gay MD, Safronenka A, Bansal S, Tucker RD, Weinberg BA, Cheema A, Shivapurkar N, Smith JP. Cholecystokinin Receptor Antagonist Improves Efficacy of Chemotherapy in Murine Models of Pancreatic Cancer by Altering the Tumor Microenvironment. Cancers (Basel) 2021;13:4949. [PMID: 34638432 DOI: 10.3390/cancers13194949] [Reference Citation Analysis]
10 Nadella S, Burks J, Al-Sabban A, Inyang G, Wang J, Tucker RD, Zamanis ME, Bukowski W, Shivapurkar N, Smith JP. Dietary fat stimulates pancreatic cancer growth and promotes fibrosis of the tumor microenvironment through the cholecystokinin receptor. Am J Physiol Gastrointest Liver Physiol 2018;315:G699-712. [PMID: 29927319 DOI: 10.1152/ajpgi.00123.2018] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
11 Bhatia V, Kim SO, Aronson JF, Chao C, Hellmich MR, Falzon M. Role of parathyroid hormone-related protein in the pro-inflammatory and pro-fibrogenic response associated with acute pancreatitis. Regul Pept 2012;175:49-60. [PMID: 22280800 DOI: 10.1016/j.regpep.2012.01.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
12 Li X, Zhao D, Guo Z, Li T, Qili M, Xu B, Qian M, Liang H, E X, Chege Gitau S, Wang L, Huangfu L, Wu Q, Xu C, Shan H. Overexpression of SerpinE2/protease nexin-1 Contribute to Pathological Cardiac Fibrosis via increasing Collagen Deposition. Sci Rep 2016;6:37635. [PMID: 27876880 DOI: 10.1038/srep37635] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
13 Dockray GJ, Moore A, Varro A, Pritchard DM. Gastrin receptor pharmacology.Curr Gastroenterol Rep. 2012;14:453-459. [PMID: 22983899 DOI: 10.1007/s11894-012-0293-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
14 Bynigeri RR, Jakkampudi A, Jangala R, Subramanyam C, Sasikala M, Rao GV, Reddy DN, Talukdar R. Pancreatic stellate cell: Pandora's box for pancreatic disease biology. World J Gastroenterol 2017; 23(3): 382-405 [PMID: 28210075 DOI: 10.3748/wjg.v23.i3.382] [Cited by in CrossRef: 82] [Cited by in F6Publishing: 75] [Article Influence: 20.5] [Reference Citation Analysis]
15 Thomas D, Radhakrishnan P. Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis. Mol Cancer. 2019;18:14. [PMID: 30665410 DOI: 10.1186/s12943-018-0927-5] [Cited by in Crossref: 93] [Cited by in F6Publishing: 93] [Article Influence: 46.5] [Reference Citation Analysis]
16 Smith JP, Cao H, Chen W, Kallakury B, Phillips T, Sutton L, Cato A. Vaccination with Polyclonal Antibody Stimulator (PAS) Prevents Pancreatic Carcinogenesis in the KRAS Mouse Model. Cancer Prev Res (Phila) 2021;14:933-44. [PMID: 34429319 DOI: 10.1158/1940-6207.CAPR-20-0650] [Reference Citation Analysis]
17 Won JH, Zhang Y, Ji B, Logsdon CD, Yule DI. Phenotypic changes in mouse pancreatic stellate cell Ca2+ signaling events following activation in culture and in a disease model of pancreatitis. Mol Biol Cell. 2011;22:421-436. [PMID: 21148289 DOI: 10.1091/mbc.e10-10-0807] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
18 Smith JP, Solomon TE. Cholecystokinin and pancreatic cancer: the chicken or the egg? Am J Physiol Gastrointest Liver Physiol. 2014;306:G91-G101. [PMID: 24177032 DOI: 10.1152/ajpgi.00301.2013] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
19 Tucker RD, Ciofoaia V, Nadella S, Gay MD, Cao H, Huber M, Safronenka A, Shivapurkar N, Kallakury B, Kruger AJ, Kroemer AHK, Smith JP. A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma. Dig Dis Sci 2020;65:189-203. [PMID: 31297627 DOI: 10.1007/s10620-019-05722-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
20 Abraham T, McGovern CO, Linton SS, Wilczynski Z, Adair JH, Matters GL. Aptamer-Targeted Calcium Phosphosilicate Nanoparticles for Effective Imaging of Pancreatic and Prostate Cancer. Int J Nanomedicine 2021;16:2297-309. [PMID: 33776434 DOI: 10.2147/IJN.S295740] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Perera CJ, Falasca M, Chari ST, Greenfield JR, Xu Z, Pirola RC, Wilson JS, Apte MV. Role of Pancreatic Stellate Cell-Derived Exosomes in Pancreatic Cancer-Related Diabetes: A Novel Hypothesis. Cancers (Basel) 2021;13:5224. [PMID: 34680372 DOI: 10.3390/cancers13205224] [Reference Citation Analysis]
22 Mohammed A, Janakiram NB, Suen C, Stratton N, Lightfoot S, Singh A, Pathuri G, Ritchie R, Madka V, Rao CV. Targeting cholecystokinin-2 receptor for pancreatic cancer chemoprevention. Mol Carcinog 2019;58:1908-18. [PMID: 31313401 DOI: 10.1002/mc.23084] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Andersen DK, Andren-Sandberg Å, Duell EJ, Goggins M, Korc M, Petersen GM, Smith JP, Whitcomb DC. Pancreatitis-diabetes-pancreatic cancer: summary of an NIDDK-NCI workshop. Pancreas 2013;42:1227-37. [PMID: 24152948 DOI: 10.1097/MPA.0b013e3182a9ad9d] [Cited by in Crossref: 98] [Cited by in F6Publishing: 54] [Article Influence: 14.0] [Reference Citation Analysis]
24 Apte MV, Pirola RC, Wilson JS. Pancreatic stellate cells: a starring role in normal and diseased pancreas. Front Physiol 2012;3:344. [PMID: 22973234 DOI: 10.3389/fphys.2012.00344] [Cited by in Crossref: 151] [Cited by in F6Publishing: 164] [Article Influence: 16.8] [Reference Citation Analysis]
25 Halbrook CJ, Pasca di Magliano M, Lyssiotis CA. Tumor cross-talk networks promote growth and support immune evasion in pancreatic cancer. Am J Physiol Gastrointest Liver Physiol 2018;315:G27-35. [PMID: 29543507 DOI: 10.1152/ajpgi.00416.2017] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
26 Nakamura T, Ito T, Uchida M, Hijioka M, Igarashi H, Oono T, Kato M, Nakamura K, Suzuki K, Jensen RT, Takayanagi R. PSCs and GLP-1R: occurrence in normal pancreas, acute/chronic pancreatitis and effect of their activation by a GLP-1R agonist. Lab Invest 2014;94:63-78. [PMID: 24217090 DOI: 10.1038/labinvest.2013.133] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
27 Uchida M, Ito T, Nakamura T, Hijioka M, Igarashi H, Oono T, Kato M, Nakamura K, Suzuki K, Takayanagi R. Pancreatic stellate cells and CX3CR1: occurrence in normal pancreas and acute and chronic pancreatitis and effect of their activation by a CX3CR1 agonist. Pancreas. 2014;43:708-719. [PMID: 24681877 DOI: 10.1097/mpa.0000000000000109] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
28 Khan S, Ebeling MC, Chauhan N, Thompson PA, Gara RK, Ganju A, Yallapu MM, Behrman SW, Zhao H, Zafar N. Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer. Cancer Res. 2015;75:2292-2304. [PMID: 25840985 DOI: 10.1158/0008-5472.can-14-2397] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 7.8] [Reference Citation Analysis]
29 Burks J, Nadella S, Mahmud A, Mankongpaisarnrung C, Wang J, Hahm JI, Tucker RD, Shivapurkar N, Stern ST, Smith JP. Cholecystokinin Receptor-Targeted Polyplex Nanoparticle Inhibits Growth and Metastasis of Pancreatic Cancer. Cell Mol Gastroenterol Hepatol 2018;6:17-32. [PMID: 29928669 DOI: 10.1016/j.jcmgh.2018.02.013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
30 Matters GL, Clawson GA. A Speculative Role for Stromal Gastrin Signaling in Development and Dissemination of Pancreatic Ductal Adenocarcinoma. Pancreat Disord Ther 2013;Suppl 4:003. [PMID: 25346875 DOI: 10.4172/2165-7092.S4-003] [Reference Citation Analysis]
31 Murthy D, Attri KS, Singh PK. Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics. Front Physiol 2018;9:335. [PMID: 29670543 DOI: 10.3389/fphys.2018.00335] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 11.7] [Reference Citation Analysis]
32 Gay MD, Safronenka A, Cao H, Liu FH, Malchiodi ZX, Tucker RD, Kroemer A, Shivapurkar N, Smith JP. Targeting the Cholecystokinin Receptor: A Novel Approach for Treatment and Prevention of Hepatocellular Cancer. Cancer Prev Res (Phila) 2021;14:17-30. [PMID: 33115780 DOI: 10.1158/1940-6207.CAPR-20-0220] [Reference Citation Analysis]
33 Wu Q, Tian Y, Zhang J, Zhang H, Gu F, Lu Y, Zou S, Chen Y, Sun P, Xu M, Sun X, Xia C, Chi H, Ying Zhu A, Tang D, Wang D. Functions of pancreatic stellate cell-derived soluble factors in the microenvironment of pancreatic ductal carcinoma. Oncotarget 2017;8:102721-38. [PMID: 29254283 DOI: 10.18632/oncotarget.21970] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
34 Smith JP, Wang S, Nadella S, Jablonski SA, Weiner LM. Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice. Cancer Immunol Immunother 2018;67:195-207. [PMID: 29043413 DOI: 10.1007/s00262-017-2077-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]